Literature DB >> 20437061

Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Katja Kollewe1, Bahram Mohammadi, Reinhard Dengler, Dirk Dressler.   

Abstract

Botulinum toxin is considered the treatment of choice for hemifacial spasm (HFS) and reinnervation synkinesias (RS). We present 133 patients with HFS (n = 97) and RS (n = 36) who have been treated with either Botox (n = 78) or Dysport (n = 55) exclusively for 6 years (range 2-12 years). The Botox dose was 21 +/- 8 MU, the Dysport dose 46 +/- 22 MU. The therapeutic effect started after 7.1 +/- 2.3 days and lasted for 12.5 +/- 3.9 weeks. It was stable throughout the observation period in 85% of all patients. Adverse effects occurred in 5.4% of injection series. No patient terminated treatment because of unsatisfactory results. Secondary therapy failure did not occur. With an effective conversion ratio of Botox:Dysport = 1:2.56 there were no differences between both drugs with respect to therapeutic efficacy and adverse effects thus confirming the hypothesis that there may not be intrinsic differences between both products.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437061     DOI: 10.1007/s00702-010-0409-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  55 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Authors:  G-Y R Hsiung; S K Das; R Ranawaya; A-L Lafontaine; O Suchowersky
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

Review 3.  Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases.

Authors:  S Jitpimolmard; S Tiamkao; M Laopaiboon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

4.  Endovascular treatment of vertebral artery aneurysm manifesting as progressive hemifacial spasm.

Authors:  Keigo Matsumoto; Satoshi Kimura; Kiyohito Kakita
Journal:  Neurol Med Chir (Tokyo)       Date:  2005-07       Impact factor: 1.742

5.  Botulinum toxin: preferred treatment for hemifacial spasm.

Authors:  M Flanders; D Chin; D Boghen
Journal:  Eur Neurol       Date:  1993       Impact factor: 1.710

Review 6.  Unusual causes of hemifacial spasm.

Authors:  N Gálvez-Jiménez; M R Hanson; M Desai
Journal:  Semin Neurol       Date:  2001       Impact factor: 3.420

Review 7.  Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review.

Authors:  H Kobata; A Kondo; K Iwasaki; T Nishioka
Journal:  Neurosurgery       Date:  1998-12       Impact factor: 4.654

8.  Hemifacial spasm: clinical findings and treatment.

Authors:  A Wang; J Jankovic
Journal:  Muscle Nerve       Date:  1998-12       Impact factor: 3.217

9.  Hemifacial spasm caused by contralateral cerebellopontine angle meningioma: case report.

Authors:  B A Rhee; T S Kim; G K Kim; W L Leem
Journal:  Neurosurgery       Date:  1995-02       Impact factor: 4.654

Review 10.  Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?

Authors:  Kai Wohlfarth; Thomas Sycha; Danièle Ranoux; Hans Naver; David Caird
Journal:  Curr Med Res Opin       Date:  2009-07       Impact factor: 2.580

View more
  11 in total

Review 1.  Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment.

Authors:  Bettina Wabbels; Peter Roggenkämper
Journal:  J Neural Transm (Vienna)       Date:  2012-01-10       Impact factor: 3.575

2.  Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.

Authors:  Katja Kollewe; Bahram Mohammadi; Steffen Köhler; Heidrun Pickenbrock; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

3.  Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.

Authors:  Katja Kollewe; Claus M Escher; Dirk U Wulff; Davood Fathi; Lejla Paracka; Bahram Mohammadi; Matthias Karst; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2016-03-31       Impact factor: 3.575

Review 4.  Treatment of Blepharospasm/Hemifacial Spasm.

Authors:  Kemar E Green; David Rastall; Eric Eggenberger
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

5.  Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.

Authors:  Ji Young Yun; Jae Woo Kim; Hee-Tae Kim; Sun Ju Chung; Jong-Min Kim; Jin Whan Cho; Jee-Young Lee; Ha Neul Lee; Sooyeoun You; Eungseok Oh; Heejeong Jeong; Young Eun Kim; Han-Joon Kim; Won Yong Lee; Beom S Jeon
Journal:  Mov Disord       Date:  2014-12-05       Impact factor: 10.338

6.  Experiences on The Administration of Botulinum Toxin in Movement Disorders.

Authors:  Buket Tuğan Yıldız; Deniz Tuncel Berktaş
Journal:  J Transl Int Med       Date:  2021-01-05

Review 7.  Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm.

Authors:  Khashayar Dashtipour; Jack J Chen; Karen Frei; Fatta Nahab; Michele Tagliati
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-10-30

Review 8.  Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Authors:  Francesco Scaglione
Journal:  Toxins (Basel)       Date:  2016-03-04       Impact factor: 4.546

Review 9.  Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies.

Authors:  Nicola Tambasco; Marta Filidei; Pasquale Nigro; Lucilla Parnetti; Simone Simoni
Journal:  Toxins (Basel)       Date:  2021-12-09       Impact factor: 4.546

10.  A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus.

Authors:  Gerard E Francisco; Alexander Balbert; Ganesh Bavikatte; Djamel Bensmail; Stefano Carda; Thierry Deltombe; Nathalie Draulans; Steven Escaldi; Raphael Gross; Jorge Jacinto; Nicholas Ketchum; Franco Molteni; Susana Moraleda; Michael W ODell; Rajiv Reebye; Patrik Säterö; Monica Verduzco-Gutierrez; Heather Walker; Jörg Wissel
Journal:  J Rehabil Med       Date:  2021-01-01       Impact factor: 2.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.